TY - GEN
T1 - Silicon Nanoneedles for Long-Term, Sustained Antibody Treatment of Ocular Angiogenesis
AU - Zheng, Mi
AU - Nguyen, Van Phuc
AU - Lee, Chi Hwan
AU - Paulus, Yannis M.
N1 - Publisher Copyright:
© 2025 IEEE.
PY - 2025
Y1 - 2025
N2 - Ocular angiogenesis, the process of neovascularization in the eye, can occur in various parts of the eye and lead to severe visual impairment. While anti-vascular endothelial growth factor (VEGF) antibody agents remain the primary treatment for this condition, their clinical efficacy is compromised by the requirement for repeated intravitreal injections - an invasive procedure associated with cumulative risks of ocular complications and patient non-compliance. This manuscript reviews the emerging utilization of silicon nanoneedles (Si NNs) as a novel drug delivery platform to address these critical challenges. We discuss the unique characteristics of Si NNs that render them suitable for ocular anti-VEGF therapy and summarize the current applications of this approach in ocular anti-VEGF treatment across diverse ocular disease models. The controlled, long-term, and sustained drug release, in conjunction with the minimal invasiveness, renders Si NNs a promising technique for ocular anti-VEGF treatment.
AB - Ocular angiogenesis, the process of neovascularization in the eye, can occur in various parts of the eye and lead to severe visual impairment. While anti-vascular endothelial growth factor (VEGF) antibody agents remain the primary treatment for this condition, their clinical efficacy is compromised by the requirement for repeated intravitreal injections - an invasive procedure associated with cumulative risks of ocular complications and patient non-compliance. This manuscript reviews the emerging utilization of silicon nanoneedles (Si NNs) as a novel drug delivery platform to address these critical challenges. We discuss the unique characteristics of Si NNs that render them suitable for ocular anti-VEGF therapy and summarize the current applications of this approach in ocular anti-VEGF treatment across diverse ocular disease models. The controlled, long-term, and sustained drug release, in conjunction with the minimal invasiveness, renders Si NNs a promising technique for ocular anti-VEGF treatment.
KW - Silicon Nanoneedles
KW - anti-VEGF treatment
KW - corneal neovascularization
KW - ocular angiogenesis
KW - ocular neovascularization
KW - retinal neovascularization
KW - vascular endothelial growth factor
UR - https://www.scopus.com/pages/publications/105014921031
UR - https://www.scopus.com/pages/publications/105014921031#tab=citedBy
U2 - 10.1109/NANO63165.2025.11113781
DO - 10.1109/NANO63165.2025.11113781
M3 - Conference contribution
AN - SCOPUS:105014921031
T3 - Proceedings of the IEEE Conference on Nanotechnology
SP - 240
EP - 244
BT - 25th IEEE International Conference on Nanotechnology, NANO 2025
A2 - Urban, Francesca
A2 - Pelella, Aniello
A2 - Di Bartolomeo, Antonio
PB - IEEE Computer Society
T2 - 25th IEEE International Conference on Nanotechnology, NANO 2025
Y2 - 13 July 2025 through 16 July 2025
ER -